In this sense, the use of inhibitors of intestinal α-glucosidase and/or pancreatic α-amylase can effectively slow the digestion and assimilation of starch at the early stages of digestion, resulting in a substantial delay in postprandial hyperglycemia and a favorable impact on insulin resistance and glycemic index regulation [2]. The gene discussed is INS; the disease is Hyperglycemia.